stoxline Quote Chart Rank Option Currency Glossary
  
iBio, Inc. (IBIO)
1.05  0 (0%)    03-18 16:00
Open: 1.07
High: 1.13
Volume: 88,601
  
Pre. Close: 1.05
Low: 1.05
Market Cap: 4(M)
Technical analysis
2024-03-18 4:44:51 PM
Short term     
Mid term     
Targets 6-month :  1.4 1-year :  1.51
Resists First :  1.2 Second :  1.29
Pivot price 1.17
Supports First :  1.04 Second :  0.87
MAs MA(5) :  1.11 MA(20) :  1.18
MA(100) :  2.38 MA(250) :  9.8
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  3.5 D(3) :  10.2
RSI RSI(14): 28
52-week High :  52 Low :  1.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IBIO ] has closed below the lower bollinger band by 2.8%. Bollinger Bands are 82.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.13 - 1.14 1.14 - 1.14
Low: 1.03 - 1.04 1.04 - 1.05
Close: 1.04 - 1.05 1.05 - 1.06
Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Headline News

Mon, 18 Mar 2024
iBio Inc. stock remains steady Monday, underperforms market - MarketWatch

Fri, 15 Mar 2024
iBio Inc. stock falls Friday, underperforms market - MarketWatch

Thu, 14 Mar 2024
Is it Time to Dump Ibio Inc (IBIO) Stock After it Has Fallen 4.24% in a Week? - InvestorsObserver

Thu, 14 Mar 2024
iBio Inc. stock falls Thursday, underperforms market - MarketWatch

Wed, 13 Mar 2024
iBio Inc. stock remains steady Wednesday, still outperforms market - MarketWatch

Tue, 12 Mar 2024
iBio Inc. stock falls Tuesday, underperforms market - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 1.4e+006 (%)
Held by Institutions 0.7 (%)
Shares Short 20 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.563e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -10 %
Return on Assets (ttm) 206 %
Return on Equity (ttm) -26.9 %
Qtrly Rev. Growth 50000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -35 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -22 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.37
Stock Dividends
Dividend 0
Forward Dividend 90540
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android